Myelodysplastic Syndrome (MDS) Pipeline Analysis 2018 – Focusing On Clinical Trials And Results, Drug Profiling, Patents, Collaborations, And Other Recent Developments
- Published : Mar 2020
- Report Code : KSI061611472
- Pages : 114
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
Myelodysplastic Syndromes (MDS) are conditions that can occur when the blood cells in the bone marrow become abnormal. It is considered as a type of cancer. Myelodysplastic syndromes affect hematopoiesis at the stem cell level, as indicated by cytogenetic abnormalities, molecular mutations, and morphologic and physiologic abnormalities in mutation and differentiation of one or more of the hematopoietic cell lines. The dysplastic cells in the bone marrow have problem in making new blood cells. Many of the blood cells formed by these bone marrow cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in myelodysplastic syndrome is a shortage of red blood cells. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages. In time, it might cause fatigue, shortness of breath, frequent infections, easy or unusual bruising or bleeding which occurs due to a low blood platelet.
The report provides Myelodysplastic Syndrome treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Sclnow Biotechnology Co. Ltd., Sumitomo Dainippon Pharma Co., Fujifilm Pharmaceuticals U.S.A., Inc., Johnson & Johnson Services, Inc., AstraZeneca, Celgene Corporation, F. Hoffmann-La Roche Ltd., Onconova Therapeutics Inc., Amgen Inc, Apogenix AG, GlaxoSmithKline plc, SymBio Pharmaceuticals, Kura Oncology, Inc., Opsona Therapeutics, CrystalGenomics Inc., Helsinn Healthcare SA., MEI Pharma Inc., Groupe Francophone des Myelodysplasies, Acceleron Pharma, Inc., Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Eli Lilly and Company, AbbVie Inc., Amphivena Therapeutics, Inc., MabVax Therapeutics Holdings, Inc., medac GmbH, Astex Pharmaceuticals, Stemline Therapeutics, Inc., Calithera Biosciences, Inc., Array BioPharma, Mirati Therapeutics, Qol-one, Syros Pharmaceuticals, Inc., Kyowa Kirin Pharmaceutical Development, Inc., Aileron Therapeutics, Medpacto, Inc., Pfizer Inc., BioMed Valley Discoveries Inc., BioLineRx., CTI BioPharma Corp., Sunesis Pharmaceuticals, Inc., Immune System Key (Isk) Ltd., Takeda Pharmaceutical Company Limited., BerGenBio ASA, Cell Medica, Forty Seven Inc., Imago BioSciences, CytoDyn Inc., OncoTherapy Science, Inc., Mateon Therapeutics, Inc., Bellicum Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited., Plexxikon, FibroGen, Inc., argenx US Inc., Kiadis Pharma, Aprea Therapeutics, Forma Therapeutics, Inc., Agios, Inc, Actinium Pharmaceuticals, Inc., Aeglea BioTherapeutics, BAYER AG, Altor BioScience, Rafael Pharmaceuticals, Inc., H3 Biomedicine Inc., Cellerant Therapeutics, Inc., and Boston Biomedical.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Sclnow Biotechnology Co. Ltd.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Sumitomo Dainippon Pharma Co.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Fujifilm Pharmaceuticals U.S.A., Inc.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Johnson & Johnson Services, Inc.,
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. AstraZeneca,
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Celgene Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. F. Hoffmann-La Roche Ltd.,
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Onconova Therapeutics Inc.,
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Amgen Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Apogenix AG,
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. GlaxoSmithKline plc.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. SymBio Pharmaceuticals,
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Kura Oncology, Inc.
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Opsona Therapeutics,
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. CrystalGenomics Inc.,
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Helsinn Healthcare SA.
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. MEI Pharma Inc.,
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Groupe Francophone des Myelodysplasies,
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Acceleron Pharma, Inc.,
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. Boehringer Ingelheim International GmbH,
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.21. Karyopharm Therapeutics,
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.22. Eli Lilly and Company,
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.23. AbbVie Inc.,
6.23.1. Introduction
6.23.2. Financials
6.23.3. Products and Services
6.23.4. SWOT
6.24. Amphivena Therapeutics Inc.,
6.24.1. Introduction
6.24.2. Financials
6.24.3. Products and Services
6.24.4. SWOT
6.25. MabVax Therapeutics Holdings, Inc.,
6.25.1. Introduction
6.25.2. Financials
6.25.3. Products and Services
6.25.4. SWOT
6.26. medac GmbH,
6.26.1. Introduction
6.26.2. Financials
6.26.3. Products and Services
6.26.4. SWOT
6.27. Astex Pharmaceuticals,
6.27.1. Introduction
6.27.2. Financials
6.27.3. Products and Services
6.27.4. SWOT
6.28. Stemline Therapeutics Inc.,
6.28.1. Introduction
6.28.2. Financials
6.28.3. Products and Services
6.28.4. SWOT
6.29. Calithera Biosciences Inc.,
6.29.1. Introduction
6.29.2. Financials
6.29.3. Products and Services
6.29.4. SWOT
6.30. Array BioPharma,
6.30.1. Introduction
6.30.2. Financials
6.30.3. Products and Services
6.30.4. SWOT
6.31. Mirati Therapeutics,
6.31.1. Introduction
6.31.2. Financials
6.31.3. Products and Services
6.31.4. SWOT
6.32. Qol-one,
6.32.1. Introduction
6.32.2. Financials
6.32.3. Products and Services
6.32.4. SWOT
6.33. Syros Pharmaceuticals Inc.,
6.33.1. Introduction
6.33.2. Financials
6.33.3. Products and Services
6.33.4. SWOT
6.34. Kyowa Kirin Pharmaceutical Development Inc.,
6.34.1. Introduction
6.34.2. Financials
6.34.3. Products and Services
6.34.4. SWOT
6.35. Aileron Therapeutics, Medpacto Inc.,
6.35.1. Introduction
6.35.2. Financials
6.35.3. Products and Services
6.35.4. SWOT
6.36. Pfizer Inc.,
6.36.1. Introduction
6.36.2. Financials
6.36.3. Products and Services
6.36.4. SWOT
6.37. BioMed Valley Discoveries Inc.,
6.37.1. Introduction
6.37.2. Financials
6.37.3. Products and Services
6.37.4. SWOT
6.38. BioLineRx.,
6.38.1. Introduction
6.38.2. Financials
6.38.3. Products and Services
6.38.4. SWOT
6.39. CTI BioPharma Corp.,
6.39.1. Introduction
6.39.2. Financials
6.39.3. Products and Services
6.39.4. SWOT
6.40. Sunesis Pharmaceuticals Inc.,
6.40.1. Introduction
6.40.2. Financials
6.40.3. Products and Services
6.40.4. SWOT
6.41. Immune System Key (Isk) Ltd.,
6.41.1. Introduction
6.41.2. Financials
6.41.3. Products and Services
6.41.4. SWOT
6.42. Takeda Pharmaceutical Company Limited.,
6.42.1. Introduction
6.42.2. Financials
6.42.3. Products and Services
6.42.4. SWOT
6.43. BerGenBio ASA,
6.43.1. Introduction
6.43.2. Financials
6.43.3. Products and Services
6.43.4. SWOT
6.44. Cell Medica,
6.44.1. Introduction
6.44.2. Financials
6.44.3. Products and Services
6.44.4. SWOT
6.45. FortySeven Inc.,
6.45.1. Introduction
6.45.2. Financials
6.45.3. Products and Services
6.45.4. SWOT
6.46. Imago BioSciences,
6.46.1. Introduction
6.46.2. Financials
6.46.3. Products and Services
6.46.4. SWOT
6.47. CytoDyn Inc.,
6.47.1. Introduction
6.47.2. Financials
6.47.3. Products and Services
6.47.4. SWOT
6.48. OncoTherapy Science Inc.,
6.48.1. Introduction
6.48.2. Financials
6.48.3. Products and Services
6.48.4. SWOT
6.49. Mateon Therapeutics Inc.,
6.49.1. Introduction
6.49.2. Financials
6.49.3. Products and Services
6.49.4. SWOT
6.50. Bellicum Pharmaceuticals, Inc.
6.50.1. Introduction
6.50.2. Financials
6.50.3. Products and Services
6.50.4. SWOT
6.51. Daiichi Sankyo Company, Limited.,
6.51.1. Introduction
6.51.2. Financials
6.51.3. Products and Services
6.51.4. SWOT
6.52. Plexxikon, FibroGen, Inc.,
6.52.1. Introduction
6.52.2. Financials
6.52.3. Products and Services
6.52.4. SWOT
6.53. argenx US Inc.,
6.53.1. Introduction
6.53.2. Financials
6.53.3. Products and Services
6.53.4. SWOT
6.54. Kiadis Pharma,
6.54.1. Introduction
6.54.2. Financials
6.54.3. Products and Services
6.54.4. SWOT
6.55. Aprea Therapeutics,
6.55.1. Introduction
6.55.2. Financials
6.55.3. Products and Services
6.55.4. SWOT
6.56. Forma Therapeutics, Inc.,
6.56.1. Introduction
6.56.2. Financials
6.56.3. Products and Services
6.56.4. SWOT
6.57. Agios, Inc.
6.57.1. Introduction
6.57.2. Financials
6.57.3. Products and Services
6.57.4. SWOT
6.58. Actinium Pharmaceuticals Inc.,
6.58.1. Introduction
6.58.2. Financials
6.58.3. Products and Services
6.58.4. SWOT
6.59. Aeglea BioTherapeutics,
6.59.1. Introduction
6.59.2. Financials
6.59.3. Products and Services
6.59.4. SWOT
6.60. BAYER AG,
6.60.1. Introduction
6.60.2. Financials
6.60.3. Products and Services
6.60.4. SWOT
6.61. Altor BioScience,
6.61.1. Introduction
6.61.2. Financials
6.61.3. Products and Services
6.61.4. SWOT
6.62. Rafael Pharmaceuticals, Inc.,
6.62.1. Introduction
6.62.2. Financials
6.62.3. Products and Services
6.62.4. SWOT
6.63. H3 Biomedicine Inc.,
6.63.1. Introduction
6.63.2. Financials
6.63.3. Products and Services
6.63.4. SWOT
6.64. Cellerant Therapeutics, Inc.,
6.64.1. Introduction
6.64.2. Financials
6.64.3. Products and Services
6.64.4. SWOT
6.65. Boston Biomedical.
6.65.1. Introduction
6.65.2. Financials
6.65.3. Products and Services
6.65.4. SWOT
6.66. Gamida Cell
6.66.1. Introduction
6.66.2. Financials
6.66.3. Products and Services
6.66.4. SWOT
List of Tables
List of Figures
Sumitomo Dainippon Pharma Co.
Fujifilm Pharmaceuticals U.S.A., Inc.
Johnson & Johnson Services, Inc.,
AstraZeneca,
Celgene Corporation
F. Hoffmann-La Roche Ltd.,
Onconova Therapeutics Inc.,
Amgen Inc.
Apogenix AG,
GlaxoSmithKline plc.
SymBio Pharmaceuticals,
Kura Oncology, Inc.
Opsona Therapeutics,
CrystalGenomics Inc.,
Helsinn Healthcare SA.
MEI Pharma Inc.,
Groupe Francophone des Myelodysplasies,
Acceleron Pharma, Inc.,
Boehringer Ingelheim International GmbH,
Karyopharm Therapeutics,
Eli Lilly and Company,
AbbVie Inc.,
Amphivena Therapeutics Inc.,
MabVax Therapeutics Holdings, Inc.,
medac GmbH,
Astex Pharmaceuticals,
Stemline Therapeutics Inc.,
Calithera Biosciences Inc.,
Array BioPharma,
Mirati Therapeutics,
Qol-one,
Syros Pharmaceuticals Inc.,
Kyowa Kirin Pharmaceutical Development Inc.,
Aileron Therapeutics, Medpacto Inc.,
Pfizer Inc.,
BioMed Valley Discoveries Inc.,
BioLineRx.,
CTI BioPharma Corp.,
Sunesis Pharmaceuticals Inc.,
Immune System Key (Isk) Ltd.,
Takeda Pharmaceutical Company Limited.,
BerGenBio ASA,
Cell Medica,
FortySeven Inc.,
Imago BioSciences,
CytoDyn Inc.,
OncoTherapy Science Inc.,
Mateon Therapeutics Inc.,
Bellicum Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited.,
Plexxikon, FibroGen, Inc.,
argenx US Inc.,
Kiadis Pharma,
Aprea Therapeutics,
Forma Therapeutics, Inc.,
Agios, Inc.
Actinium Pharmaceuticals Inc.,
Aeglea BioTherapeutics,
BAYER AG,
Altor BioScience,
Rafael Pharmaceuticals, Inc.,
H3 Biomedicine Inc.,
Cellerant Therapeutics, Inc.,
Boston Biomedical.
Gamida Cell